Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.052 SGD | -1.89% | +13.04% | +15.56% |
Mar. 12 | Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer | MT |
Mar. 12 | IX Biopharma Introduces New Sublingual Wafer | MT |
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.56% | 29.61M | - | - | |
+33.46% | 701B | C+ | ||
+26.24% | 570B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 322B | C+ | ||
+2.95% | 212B | B- | ||
+0.74% | 209B | B+ | ||
-6.05% | 205B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock iX Biopharma Ltd. - Singapore S.E.
- Ratings iX Biopharma Ltd.